Free Trial

Bristol Myers Squibb (BMY) Stock Price, News & Analysis

Bristol Myers Squibb logo
$46.34 -0.31 (-0.66%)
Closing price 06/27/2025 03:59 PM Eastern
Extended Trading
$46.30 -0.05 (-0.10%)
As of 06/27/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Bristol Myers Squibb Stock (NYSE:BMY)

Key Stats

Today's Range
$46.18
$46.95
50-Day Range
$44.06
$50.68
52-Week Range
$39.35
$63.33
Volume
21.85 million shs
Average Volume
12.89 million shs
Market Capitalization
$94.31 billion
P/E Ratio
17.36
Dividend Yield
5.35%
Price Target
$58.00
Consensus Rating
Hold

Company Overview

Bristol Myers Squibb (NYSE: BMY) is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious diseases. With roots tracing back to the founding of Bristol-Myers in 1887 and E.R. Squibb & Sons in 1858, the company merged in 1989 to combine decades of expertise in pharmaceutical research and development. Today, Bristol Myers Squibb concentrates on four therapeutic areas—oncology, hematology, immunology and cardiovascular disease—seeking to address unmet medical needs through both small molecules and biologics.

The company’s product portfolio includes leading therapies such as the immuno-oncology agents Opdivo and Yervoy, the blood cancer therapy Revlimid, the rheumatoid arthritis treatment Orencia, and the cardiovascular medicine Eliquis. In addition to its marketed drugs, Bristol Myers Squibb maintains a robust pipeline of clinical and preclinical candidates in areas like fibrosis, neuroscience and cell therapy. Research efforts are supported by collaborations with academic institutions and biotech partners, reflecting a commitment to science-driven innovation.

Bristol Myers Squibb operates in more than 60 countries, with major research hubs in North America, Europe and Asia, and manufacturing facilities across key regions. The company’s global footprint enables it to serve diverse patient populations and navigate complex regulatory environments. Through its network of subsidiaries and joint ventures, Bristol Myers Squibb also strives to improve patient access to therapies in emerging markets and under-resourced communities.

Under the leadership of Chairman and Chief Executive Officer Giovanni Caforio, M.D., Bristol Myers Squibb emphasizes strong corporate governance, sustainability and social responsibility. The executive team and board of directors oversee strategic initiatives aimed at enhancing research productivity, driving operational efficiency and fostering a culture of inclusivity and ethical conduct within the organization.

AI Generated. May Contain Errors.

Bristol Myers Squibb Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
100th Percentile Overall Score

BMY MarketRank™: 

Bristol Myers Squibb scored higher than 100% of companies evaluated by MarketBeat, and ranked 7th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bristol Myers Squibb has received a consensus rating of Hold. The company's average rating score is 2.32, and is based on 5 buy ratings, 13 hold ratings, and 2 sell ratings.

  • Amount of Analyst Coverage

    Bristol Myers Squibb has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Bristol Myers Squibb's stock forecast and price target.
  • Earnings Growth

    Earnings for Bristol Myers Squibb are expected to decrease by -9.64% in the coming year, from $6.74 to $6.09 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bristol Myers Squibb is 17.36, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.00.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bristol Myers Squibb is 17.36, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.15.

  • Price to Earnings Growth Ratio

    Bristol Myers Squibb has a PEG Ratio of 1.37. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Bristol Myers Squibb has a P/B Ratio of 5.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Bristol Myers Squibb's valuation and earnings.
  • Percentage of Shares Shorted

    1.66% of the float of Bristol Myers Squibb has been sold short.
  • Short Interest Ratio / Days to Cover

    Bristol Myers Squibb has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bristol Myers Squibb has recently increased by 3.29%, indicating that investor sentiment is decreasing.
  • Dividend Leadership

    Bristol Myers Squibb is a leading dividend payer. It pays a dividend yield of 5.35%, putting its dividend yield in the top 25% of dividend-paying stocks.

  • Dividend Growth

    Bristol Myers Squibb has been increasing its dividend for 17 years.

  • Dividend Coverage

    The dividend payout ratio of Bristol Myers Squibb is 92.88%. Payout ratios above 75% are not desirable because they may not be sustainable.

  • Dividend Sustainability

    Based on earnings estimates, Bristol Myers Squibb will have a dividend payout ratio of 40.72% next year. This indicates that Bristol Myers Squibb will be able to sustain or increase its dividend.

  • Read more about Bristol Myers Squibb's dividend.
  • Percentage of Shares Shorted

    1.66% of the float of Bristol Myers Squibb has been sold short.
  • Short Interest Ratio / Days to Cover

    Bristol Myers Squibb has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bristol Myers Squibb has recently increased by 3.29%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Bristol Myers Squibb has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.93 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 51 news articles for Bristol Myers Squibb this week, compared to 38 articles on an average week.
  • Search Interest

    130 people have searched for BMY on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.
  • MarketBeat Follows

    Only 21 people have added Bristol Myers Squibb to their MarketBeat watchlist in the last 30 days. This is a decrease of -49% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bristol Myers Squibb insiders have bought 5,384.54% more of their company's stock than they have sold. Specifically, they have bought $202,215.00 in company stock and sold $3,687.00 in company stock.

  • Percentage Held by Insiders

    Only 0.07% of the stock of Bristol Myers Squibb is held by insiders.

  • Percentage Held by Institutions

    76.41% of the stock of Bristol Myers Squibb is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Bristol Myers Squibb's insider trading history.
Receive BMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bristol Myers Squibb and its competitors with MarketBeat's FREE daily newsletter.

BMY Stock News Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
See More Headlines

BMY Stock Analysis - Frequently Asked Questions

Bristol Myers Squibb's stock was trading at $56.56 at the start of the year. Since then, BMY shares have decreased by 18.1% and is now trading at $46.3410.
View the best growth stocks for 2025 here
.

Bristol Myers Squibb Company (NYSE:BMY) announced its quarterly earnings data on Thursday, April, 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.50 by $0.30. The business's revenue for the quarter was down 5.6% on a year-over-year basis.
Read the conference call transcript
.

Bristol Myers Squibb's stock split on Thursday, June 26th 2014.The 2-1 split was announced on Thursday, June 19th 2014. The newly created shares were issued to shareholders after the market closes on Wednesday, June 25th 2014. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Bristol Myers Squibb's board authorized a share buyback plan on Thursday, December 7th 2023, which authorizes the company to buy back $3,000,000,000 in shares, according to EventVestor. This means that the company could buy up to 2.9% of its stock through open market purchases. Stock buyback plans are generally a sign that the company's management believes its stock is undervalued.

Bristol Myers Squibb subsidiaries include MyoKardia, Forbius, Celgene, IFM Therapeutics, Cormorant Pharmaceuticals, Padlock Therapeutics, Cardioxyl Pharmaceuticals, and more.

Shares of BMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bristol Myers Squibb investors own include Chevron (CVX), Comcast (CMCSA), McKesson (MCK), Charles Schwab (SCHW), Edwards Lifesciences (EW), Yum! Brands (YUM) and Toronto Dominion Bank (TD).

Company Calendar

Record date for 5/1 Dividend
4/04/2025
Ex-Dividend for 5/1 Dividend
4/04/2025
Last Earnings
4/24/2025
Dividend Payable
5/01/2025
Today
6/29/2025
Record date for 8/1 Dividend
7/03/2025
Ex-Dividend for 8/1 Dividend
7/03/2025
Next Earnings (Estimated)
7/31/2025
Dividend Payable
8/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceuticals
Current Symbol
NYSE:BMY
Employees
34,300
Year Founded
1887

Price Target and Rating

Average Stock Price Target
$58.00
High Stock Price Target
$73.00
Low Stock Price Target
$39.00
Potential Upside/Downside
+25.2%
Consensus Rating
Hold
Rating Score (0-4)
2.32
Research Coverage
22 Analysts

Profitability

Trailing P/E Ratio
17.36
Forward P/E Ratio
6.88
P/E Growth
1.37
Net Income
-$8.95 billion
Pretax Margin
12.82%

Debt

Sales & Book Value

Annual Sales
$48.30 billion
Cash Flow
$5.89 per share
Price / Cash Flow
7.87
Book Value
$8.08 per share
Price / Book
5.74

Miscellaneous

Outstanding Shares
2,035,080,000
Free Float
2,033,656,000
Market Cap
$94.31 billion
Optionable
Optionable
Beta
0.38

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NYSE:BMY) was last updated on 6/30/2025 by MarketBeat.com Staff
From Our Partners